Amenamevir

Generic Name: Amenamevir

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₆N_₄O_₅S

CAS Number: 841301-32-4

Unique Ingredient Identifier: 94X46KW4AE

Background: Amenamevir has been used in trials studying the treatment of Herpes Zoster, Herpes Simplex, Herpes Genitalis, and Safety of Amenamevir.

Clinical Trials

Study to Evaluate the Safety and Pharmacokinetics of Single Doses of ASP2151 in Healthy Male Subjects and the Effects of Food

Phase 1

Completed

Conditions: Herpes Genitalis
Herpes Zoster

Interventions: Drug: ASP2151
Drug: Placebo

First Posted Date: 2016-08-02

Last Posted Date: 2016-08-02

Lead Sponsor: Astellas Pharma Europe Ltd.

Target Recruit Count: 72

Registration Number: NCT02852876

Locations: 🇫🇷
Site FR1717, Paris, France

Study to Evaluate the Safety and Pharmacokinetics of ASP2151 in Healthy Non-elderly and Elderly Subjects

Phase 1

Completed

Conditions: Healthy Subjects

Interventions: Drug: ASP2151
Drug: Placebo

First Posted Date: 2016-06-10

Last Posted Date: 2016-08-29

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 36

Registration Number: NCT02796118

Locations: 🇯🇵
Site JP00001, Osaka, Japan

Drug-Drug Interaction Study: ASP2151 and Midazolam

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Midazolam
Drug: ASP2151

First Posted Date: 2015-03-31

Last Posted Date: 2019-02-21

Lead Sponsor: Maruho Europe Limited

Target Recruit Count: 27

Registration Number: NCT02403635

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

Drug-Drug Interaction Study: ASP2151 and Bupropion

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Bupropion
Drug: ASP2151

First Posted Date: 2015-02-23

Last Posted Date: 2019-02-21

Lead Sponsor: Maruho Europe Limited

Target Recruit Count: 24

Registration Number: NCT02369172

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

Drug-Drug Interaction Study: ASP2151 and Montelukast

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Montelukast
Drug: ASP2151

First Posted Date: 2014-12-22

Last Posted Date: 2019-02-27

Lead Sponsor: Maruho Europe Limited

Target Recruit Count: 24

Registration Number: NCT02321748

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

Drug-Drug Interaction Study: ASP2151 and Ritonavir

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ASP2151
Drug: ritonavir

First Posted Date: 2014-08-22

Last Posted Date: 2019-02-27

Lead Sponsor: Maruho Europe Limited

Target Recruit Count: 48

Registration Number: NCT02223351

Locations: 🇬🇧
Hammersmith Medicines Research Ltd, London, United Kingdom

Open-label Study of ASP2151 in Herpes Simplex Patients

Phase 3

Completed

Conditions: Herpes Simplex

Interventions: Drug: ASP2151

First Posted Date: 2014-08-05

Last Posted Date: 2016-03-16

Lead Sponsor: Maruho Co., Ltd.

Target Recruit Count: 250

Registration Number: NCT02209324

Locations: 🇯🇵
Oota-ku Tokyo Japan, Tokyo, Japan
🇯🇵
Sapporo Hokkaido Japan, Sapporo, Japan
🇯🇵
Yokohama Kanagawa Japan, Yokohama, Japan

Phase III Study of ASP2151 in Herpes Zoster Patients

Phase 3

Completed

Conditions: Herpes Zoster

Interventions: Drug: ASP2151
Drug: valaciclovir

First Posted Date: 2013-10-10

Last Posted Date: 2018-11-27

Lead Sponsor: Maruho Co., Ltd.

Target Recruit Count: 751

Registration Number: NCT01959841

Phase III Study of ASP2151 in Herpes Simplex Patients

Phase 3

Completed

Conditions: Herpes Simplex

Interventions: Drug: ASP2151 placebo
Drug: ASP2151

First Posted Date: 2013-10-10

Last Posted Date: 2024-10-09

Lead Sponsor: Maruho Co., Ltd.

Target Recruit Count: 468

Registration Number: NCT01959295

Study Comparing the Safety of ASP2151 to Valacyclovir and Placebo in Healthy Volunteers

Phase 1

Terminated

Conditions: Safety of ASP2151

Interventions: Drug: ASP2151
Drug: Valacyclovir
Drug: Placebo

First Posted Date: 2009-03-27

Last Posted Date: 2013-02-28

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 442

Registration Number: NCT00870441

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy